Polymer Capital Management HK LTD Takes $1.24 Million Position in DBV Technologies S.A. $DBVT

Posted by Brenda Bartman on Jun 13th, 2026

Polymer Capital Management HK LTD bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT – Free Report) during the 4th quarter, Holdings Channel reports. The fund bought 64,500 shares of the company’s stock, valued at approximately $1,236,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allworth Financial LP purchased a new stake in DBV Technologies in the fourth quarter worth $32,000. GAMMA Investing LLC lifted its holdings in shares of DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares in the last quarter. New York State Common Retirement Fund bought a new position in shares of DBV Technologies during the third quarter valued at $34,000. Two Sigma Investments LP bought a new position in shares of DBV Technologies during the third quarter valued at $167,000. Finally, Citadel Advisors LLC bought a new position in shares of DBV Technologies during the third quarter valued at $220,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DBVT has been the topic of a number of recent research reports. Guggenheim reissued a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a report on Monday, May 4th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Citizens Jmp raised their price target on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

View Our Latest Report on DBVT

DBV Technologies Stock Performance

Shares of DBVT stock opened at $17.42 on Friday. The stock has a 50 day moving average price of $19.42 and a 200 day moving average price of $19.64. The firm has a market capitalization of $1.03 billion, a P/E ratio of -3.91 and a beta of -0.99. DBV Technologies S.A. has a 52-week low of $8.50 and a 52-week high of $26.18.

DBV Technologies (NASDAQ:DBVT – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). The firm had revenue of $0.90 million for the quarter, compared to the consensus estimate of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. As a group, sell-side analysts forecast that DBV Technologies S.A. will post -0.47 EPS for the current year.

DBV Technologies Profile

(Free Report)

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.